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Introduction
Human polyomavirus BK (BKV) is a highly prevalent virus characterized by latency in uroepithelial cells and other sites. In renal transplantation, in the context of intense immunosuppression, BKV can reactivate from latency resulting in BKV-associated nephropathy with interstitial nephritis and/or ureteral stenosis in 1-10% of the patients, leading to graft failure and return in hemodialysis in 30 up to 80% of the cases (1-3) .
Screening for polyomavirus replication, by urine and serum viral load quantitation (4,5), may allow for earlier intervention with reduced allograft loss (2). Ding et al. (6) proposed the measurement of urinary cell BKV VP1 mRNA for identify viral replication levels at risk of developing nephropathy. Although there is no definitive cut-off for BKV VP1 mRNA levels diagnostic of nephropathy, Dadhania et al. (7) found that the median BKV VP1 copy number in renal transplant patients with BKV replication without nephropathy was significantly lower in comparison to that reported in renal allograft recipients with biopsy proven nephropathy (267 BKV VP1 copies/pg of total RNA vs. 34,000, p = 0.004).
In this paper the development, optimization, and standardization of a Taqman Real-Time reverse transcription (RT)-PCR assay for the quantitation of BKV VP1 mRNA levels in urine is described. Subsequently, the method has been validated on urine specimens obtained from renal transplant recipients. 
Materials and methods

Clinical samples
Two-hundred-seventeen urine and 217 serum specimens from 114 renal transplant recipients (61 males, 53 females; men age ± standard deviation, 56.9±9.7 years; range, 29-77) were studied. The occurrence of BKV-associated nephropathy was diagnosed by histopathological evaluation on kidney graft biopsy, that was collected in the presence of renal function abnormalities and/or on the basis of clinical features suggestive of nehropathy and/or rejection.
Nucleic acid extraction
Automated extraction of total nucleic acids from urine samples was performed with the NucliSens easyMAG platform (bioMeriéux, Marcy l'Etoile, France). As regards total RNA, extracted specimens were subjected to RQ1 RNase-Free DNase digestion (Promega, Milan, Italy), following the manufacturer's instruction. A second automated extraction was performed in order to remove the DNase buffer that could interfere with the amplification.
The absence of contaminating DNA was ascertained by PCR amplification (see section 2.3), following the second extraction, that tested negative.
Real Time PCR for BKV-DNA quantitation in serum and urine samples
BKV DNA quantitation was performed by Real Time TaqMan PCR using a commercial kit (BKV Q-PCR Alert Kit; Nanogen Advanced Diagnostic, Milano, Italy) for the detection of the target viral gene encoding for the large T-antigen of BKV with the 7300 Real Time PCR System (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions and as described previously (4). Briefly, PCR amplifications were set up in a reaction volume of 25 μl that contained 5 μl of extracted sample or negative control (sterile double-distilled H 2 O) or plasmid. The assay is linear in the range 10 1 -10 6 copies per reaction, corresponding to an absolute quantitation of 10 3 copies/ml.
Plasmids
The plasmid pBKV (ATCC 33-1 [ATCC, Manassas, VA]), containing the complete genome sequence of BKV (linearized using restriction enzyme BamHI) and cloned into the pBR322 chemically-competent cells (Invitrogen), according to the manufacturer's instructions.
cRNA standard production
A large amount of cRNA of the pBKV was obtained by using the T7 RiboMAX Express Large Scale RNA Production System (Promega), according to the manufacturer's instructions. After the transcription, the DNA template was removed by adding RQ1
RNase-free DNase to a concentration of 1 U/μg DNA. After incubation at 37°C for 15 min., the RNA was purified by performing two automated extractions with the NucliSens easyMAG instrument (bioMeriéux). The concentration of BKV-cRNA was estimated by spectrophotometric reading at OD 260 . To determine the sensitivity of the RT-PCR assay, stock preparations of BKV-cRNA were diluted to 10 -1 copies/μl by serial 10-fold dilutions. To simulate the natural specimen, BKV-cRNA was extracted in parallel with the nucleic acid of the sample.
Reverse transcription
The RT reaction was done by a random cDNA syntesis from 10 µl of extracted sample RNA in two step: first a reaction mixture containing random primers (50 ng/ml)(Invitrogen) and 10 mM dNTPs (Invitrogen, Carlsbad, CA) was added and incubated at 65°C for 5 min. The sensitivity of Real Time PCR assays is defined as the lowest concentration of target quantified at a frequency of 100%. The dynamic range (or linearity rate) was evaluated using 10-fold dilutions (from 10 10 to 10 0 copies/reaction) of BKV-cRNA standard. Precision or intra-and inter-assay variability (CV) was evaluated using different concentrations of standard BKV-cRNA (ranging from 10 5 to 10 2 copies/reaction) within a single run (n = 10) or different run experiments (n = 10) with single replicates of each concentration considered as an unknown specimen. The primers were tested for potential crossreactivity with related viral sequences of polyomaviruses JC, SV40, KI and WU based on the data available at the BLAST alignment software. Similarly, BLAST was also performed on short fragments (primers lacking at the 3'end down to 15 nucleotides).
In order to ascertain the identity of the resulting products a cycle sequencing was performed. PCR amplification products were used as templates for DNA sequencing using the BigDye Terminator chemistry, following the manufacturer's instructions (BigDye mRNA copy number was >10 3 /10 3 cells.
Statistical analysis
The coefficient of variation for samples quantified in repeated measurements was calculated. Descriptive statistics were expressed as absolute value and percentage. For statistical analysis the t test was used. Operating characteristics, including sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were evaluated by using a commercially available software (MedCalc; version 9.2.1.0). 
Optimization, standardization, and validation of Real Time PCR assays
The following primer/probe and MgCl 2 concentrations were chosen: 0.25 mM/0.18 mM and 3 mM MgCl 2 , and 0.5 mM/0.25 mM and 3 mM MgCl 2 for VP1 and GAPDH, respectively.
The dynamic range of the home-made Real Time PCR for VP1 was evaluated by carrying out serial dilutions of BKV-cRNA (from 10 10 to 10 0 copies/reaction), and ranged from 10 8 to 10 2 . The sensitivity of the assays was 10 copies/reaction. The precision, defined as the level of concordance of the individual test results within a single round (intra-assay precision) and from one run to another (inter-assay precision), was evaluated using different concentrations of BKV-cRNA, ranging from 10 5 to 10 2 copies/reaction, and is reported in Table 1 .
Clinical samples
Results are summarized in Table 2 . Based on urine VP1 mRNA measurement, BKV replication was found in 31/217 (14.3%) specimens from 20/114 (17.6%) patients; in particular, 15 specimens (6.9%) of 9 patients (7.9%) with levels >10 4 copies/10 3 cells and 5
(2.3%) of 3 (2.6%) >10 5 . As regards viremia and viruria, BKV-DNA resulted positive (above 10 3 copies/ml) in 18 (8.3%9 and 23 (10.6%) serum and urine specimens, respectively from 9 (7.9%) and 15 (13.2%) patients. A histologically confirmed diagnosis of BKVAN was made in two patients, both with VP1 mRNA levels >10 5 (66.7% of patients above this cutoff level) and with serum BKV-DNA >1 x 10 6 copies/ml (66.7% of patients above this cutoff level). Urine VP1 mRNA was detected in all the cases, except five, in association to viremia and in all the cases to viruria. Considering the highest level in each patient, median urine VP1 mRNA level was 31236 copies/10 3 cells; no difference of VP1 mRNA levels was found between the two patients who developed BKVAN and the highest values 
Discussion
In this paper the optimization and standardization of a Real-time RT-PCR assay for the quantitation of urine VP1 mRNA levels is described. This method was first proposed by in shedding of urothelially derived decoy cells in high number and only replicating BKV leads to these cytopathic changes and the shedding of decoy cells in urine. In this study, the measurement of VP1 mRNA copies has been normalized on the basis of the number of urinary cells, rather than on the amount of total RNA. Because decoy cells mostly contain BK virus antigens (9), it is likely that extracted mRNA originated from these cells.
Therefore, the availability of a RT-PCR that normalized the measurement of BKV VP1 mRNA on the basis of the number of cells could be useful for investigating the relationship 
